Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomized, Multicenter Study. Lancet 2020;395:1208

Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomized, Multicenter Study. Lancet 2020;395:1208–16

Published:2020-10 Issue:5 Volume:3 Page:713
ISSN:2588-9311
Container-title:European Urology Oncology
language:en
Short-container-title:European Urology Oncology

Author:

Evangelista Laura^ORCID,De Salvo Gian Luca,Zattoni Fabio^ORCID,Novara Giacomo

Publisher

Elsevier BV

Subject

Urology,Radiology Nuclear Medicine and imaging,Oncology,Surgery

Reference4 articles.

1. Prostate-specific membrane antigen PET-CT in patients with high-risk cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomized, multicenter study;Hofman;Lancet,2020

2. Number of unfavorable intermediate-risk factors predicts pathologic upstaging and prostate cancer-specific mortality following radical prostatectomy: results from the SEARCH database;Zumsteg;Prostate,2017

3. Improvement of the intermediate risk prostate cancer sub-classification by integrating MRI and fusion biopsy features;Roumiguie;Urol Oncol,2020

4. Added value of cost-utility analysis in simple diagnostic studies of accuracy: 18F-fluoromethylcholine PET/CT in prostate cancer staging;Gerke;Am J Nucl Med Mol Imaging,2015

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Automatic Whole Body FDG PET/CT Lesion Segmentation using Residual UNet and Adaptive Ensemble;2023-02-07

2. Improvements in Prostate Cancer Management: Focus on Imaging and Treatment;EMJ Urology;2022-08-15